Aclarion Inc. (ACON) Financial Statements (2025 and earlier)

Company Profile

Business Address 8181 ARISTA PLACE
BROOMFIELD, CO 80021
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 8071 - Medical Laboratories (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,1732,1331,021161605448
Cash and cash equivalents1,1732,1331,021161605448
Receivables201713211017
Deferred costs  205   
Other undisclosed current assets65938850182183210
Total current assets:1,8522,5381,289365798676
Noncurrent Assets
Property, plant and equipment112223
Intangible assets, net (including goodwill)1,2361,1871,1691,1761,2041,183
Intangible assets, net (excluding goodwill)1,2361,1871,1691,1761,2041,183
Other undisclosed noncurrent assets     (0) 
Total noncurrent assets:1,2371,1891,1701,1781,2061,186
Other undisclosed assets     0 
TOTAL ASSETS:3,0893,7272,4601,5432,0041,861
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities179196761698761602
Accounts payable179196761686608545
Accrued liabilities    1215457
Debt 7776701,126728238 
Derivative instruments and hedges, liabilities 1933121367172 
Other undisclosed current liabilities4723231,180578823135
Total current liabilities:1,4471,2223,1882,3711,994736
Noncurrent Liabilities
Total liabilities:1,4471,2223,1882,3711,994736
Equity
Equity, attributable to parent1,6422,505(728)(828)101,125
Common stock000000
Additional paid in capital49,56149,18643,55442,18842,02841,679
Accumulated deficit(47,919)(46,681)(44,282)(43,016)(42,018)(40,554)
Total equity:1,6422,505(728)(828)101,125
Other undisclosed liabilities and equity     0 
TOTAL LIABILITIES AND EQUITY:3,0893,7272,4601,5432,0041,861

Income Statement (P&L) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Revenues111014191725
Cost of revenue(23)(19)(19)(20)(19)(17)
Gross profit:(12)(9)(6)(0)(2)8
Operating expenses(1,123)(1,266)(1,121)(1,162)(1,404)(1,189)
Other undisclosed operating income   0   
Operating loss:(1,136)(1,275)(1,126)(1,162)(1,406)(1,181)
Nonoperating income (expense)(103)(1,124)(139)164(58)(2)
Other nonoperating income (expense)(0)93(1)01(1)
Interest and debt expense  (112)(393)(166)(47)(1)
Loss from continuing operations before equity method investments, income taxes:(1,238)(2,511)(1,659)(1,164)(1,512)(1,185)
Other undisclosed income from continuing operations before income taxes  11239316647 
Loss from continuing operations:(1,238)(2,399)(1,265)(998)(1,465)(1,185)
Other undisclosed net income (loss)     1
Net loss:(1,238)(2,399)(1,265)(998)(1,465)(1,183)
Other undisclosed net income attributable to parent      
Net loss attributable to parent:(1,238)(2,399)(1,265)(998)(1,465)(1,183)
Preferred stock dividends and other adjustments      
Net loss available to common stockholders, diluted:(1,238)(2,399)(1,265)(998)(1,465)(1,183)

Comprehensive Income ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Net loss:(1,238)(2,399)(1,265)(998)(1,465)(1,183)
Comprehensive loss, net of tax, attributable to parent:(1,238)(2,399)(1,265)(998)(1,465)(1,183)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: